An Open Label Dose Escalation Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure.

Trial Profile

An Open Label Dose Escalation Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs JVS 100 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2012 12-month results were presented at the 7th International Conference on Cell Therapy for Cardiovascular Disease, according to a Juventas Therapeutics media release. The results were also presented in the media release.
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 24 May 2011 Results were presented at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top